ArticleIrish journal of medical science2025
PHLPP and LAMP2 predict favorable treatment response and survival in multiple myeloma patients who receive induction treatment with bortezomib.
Article in Irish journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP) increases the sensitivity of multiple myeloma (MM) cells to bortezomib by upregulating lysosome-associated membrane protein 2 (LAMP2), while their clinical role in MM patients is unclear. This study aimed to assess the intercorrelation between PHLPP and LAMP2, as well as their associations with treatment response and survival in MM patients who received induction treatment with bortezomib.
methodsA total of 59 MM patients who received induction treatment with bortezomib were included. PHLPP and LAMP2 were detected by quantitative polymerase chain reaction in bone marrow plasma cells that were collected before treatment. Treatment response, progression-free survival (PFS), and overall survival (OS) were assessed.
resultsPHLPP was positively correlated with LAMP2, whether they were considered as continuous variables (r = 0.469, P < 0.001) or categorized as high and low expressions (P = 0.003). PHLPP and LAMP2 were elevated in patients who achieved complete remission (CR) versus those who did not, as well as in patients who achieved partial remission (PR) and above versus those who had less than PR (all P < 0.05). By chi-square test, high PHLPP (cut by the median) was linked with the achievement of PR and above (P = 0.015), and high LAMP2 (cut by the median) was related to the achievement of CR (P = 0.030). High PHLPP (P = 0.016) and LAMP2 (P = 0.037) were associated with prolonged PFS, but not OS (both P > 0.05).
conclusionPHLPP is positively correlated with LAMP2, and their high expressions predict favorable treatment response and PFS in MM patients who receive induction treatment with bortezomib.
Indexed as
Identifiers
39951232What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.